Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy.

SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

I’m a 64-year-old man who was recently diagnosed with an enlarged prostate after experiencing issues with frequent urination, ...

UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM ESTCompany ParticipantsJames Clemmer - CEO, President ...

A new procedure now available at Columbus Regional aims to give men with enlarged prostates a chance to reclaim their ...

Hyderabad: The Asian Institute of Nephrology & Urology (AINU) has launched a Men’s Wellness Program at its Banjara Hills ...

A prostate cancer diagnosis and life during and after treatments can feel overwhelming. Alongside the shock of a diagnosis, ...

Despite SBRT to oligometastatic sites, prostate cancer progression still occurs in a majority of patients due to occult microscopic disease.

Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a chemical imaging probe that resists the breakdown of certain compounds in the body, giving doctors ...

One of the biggest concerns is something known as benign prostatic hyperplasia. Simply put, that's an enlarged prostate.

Bursts of electrical stimulation could help restore gut motion to treat constipation, a technique recently licensed by industry leader Boston Scientific ...